Our latest lead by Dr. Katy Abel. More evidence that underutilization of NACT is associated with worse post-operative outcomes, without any hint of long-term benefit, even in high-volume centers.

Our JAMA Oncology study is now featured in the @IJGConline podcast! Thank you for highlighting our work. Grateful to work with such an amazing team! @dviverosc @headofmelon @NiteckiRoni @RParejaGineOnco @RauhHainMD

https://t.co/bwx6SuLOLI

Our 15-year cohort study explores trends in surgical de-escalation in gynecologic oncology. These findings are transforming patient care but raise important questions about the preparation of fellows in surgical training. @headofmelon @dviverosc @RauhHainMD @NiteckiRoni

LANCE trial lead-in pilot shows the feasibility of a phase III study to evaluate the efficacy of MIS for interval cytoreduction in ovarian cancer. @RauhHainMD @annafagottimd @RParejaGineOnco @pedroramirezMD @abedsinno

#cancer during #pregnancy is associated with severe maternal and neonatal morbidity. Proud of the entire team for this important manuscript! https://t.co/qB7QRETVkK @RauhHainMD @headofmelon @markaclapp @abigailflynt @dviverosc @nagustiga @MDAndersonNews @AJOG_thegray

What an honor for us to host @scambiagiovanni and @annafagottimd at @MghObgyn.

Cool picture of a adenosarcoma assocaited uterine inversion which we treated laparoscopically. Nice work by Baran Vardar and @AlexBercowMD getting these pictures into the literature. https://t.co/D6Yy7Erjpp

https://t.co/pfYw7uNQmM

Josseli Barnica is the victim of a totalitarian state imposing its ideology on women’s bodies. America we are better than this.

NACT and interval cytoreductive surgery edges out primary cytoreductive surgery as the most frequent treatment for advanced-stage ovarian cancer in the US. 11 years after Vergote et al. It really does take a decade.

Since 2021, neoadjuvant chemotherapy followed by interval cytoreductive surgery has become the most prevalent approach of upfront treatment for patients with advanced epithelial ovarian cancer in the US.

Thanks @IJGConline and @pedroramirezMD for this great honor.

A new paper by super intern Katy Abel looks at the use and efficacy of primary site surgery in metastatic cancer. There is a lot of heterogeneity across cancer sites, raising essential questions about how, and if, we know when surgery is helpful https://t.co/DRXYL9mUcp

A new paper by Jason Silberman @JSilby3: who is on the market for the gyn onc fellowship spot! https://t.co/96GXOnqXyW cytotoxic NACT has increased for stage III&IV low-grade serous ovarian cancer in last 15y w/o evidence that this approach is effective in this cancer type

Nice study from Vrede et al: The molecular subtype may not be prognostically important for low-grade endometrioid endometrial cancer Relevance of Molecular Profiling in Patients With Low-Grade Endometrial Cancer https://t.co/uGKtQQS9lz via @JAMANetworkOpen part of @JAMANetwork

Our latest study in @JAMASurgery revealed that spending for cancer surgery decreased significantly among Medicare beneficiaries. Read the full text: https://t.co/u3sniF1G6G @headofmelon @NancyKeatingMD @anaeze_offodile

If you last checked in on AI image makers a month ago & thought “that is a fun toy, but is far from useful…” Well, in just the last week or so two of the major AI systems updated. You can now generate a solid image in one try. For example, “otter on a plane using wifi” 1st try:

The dramatic difference between leg room one gets in economy compared to economy plus seems like an ominous symptom of declining solidarity in US society. But also: I’m never flying regular economy again.

When you ask the intern for the patient’s oncologic history on rounds: